Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...

Cancer imposes catastrophic health expenditure in India, with medicines constituting over 60% of out-of-pocket expenditure.

HER2 and ABCC1 are identified as significant transcriptomic predictors of overall survival in patients treated with T-DXd. A large-scale analysis reveals novel predictors of survival and resistance ...

The move can significantly lower out‑of‑pocket burdens for families, given that India’s health insurance coverage for ...

Beyond drugs and manufacturing, the Union Budget 2026-27 proposes significant structural upgrades to India's healthcare ...

Researchers have revealed how patients with metastatic breast cancer develop resistance to Enhertu treatment.

Emerging immunotherapies and targeted therapies take aim at recently identified biomarkers ...

Immunotherapy, targeted treatments, HIPEC, and new delivery options ...

In the fourth quarter of 2025, Samsung Bioepis achieved a consolidated revenue of KRW 429.4 billion with an operating profit of KRW 29.2 billion. Revenue and operating profit based on product sales ...

As of Friday, January 30, ALX Oncology Holdings Inc.’s ALXO share price has surged by 8.28%, which has investors questioning if this is right time to sell.

Precision medicine in endometrial cancer emphasizes molecular drivers, challenging traditional histopathologic approaches and ...